Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × lortalamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1 Neoplasms 1

Interventions

Cyclophosphamide 41 fludarabine 31 Dexamethasone 27 venetoclax 24 Cytarabine 22 Rituximab 16 pembrolizumab 14 fludarabine phosphate 14 Filgrastim 12 Etoposide 12 Lenalidomide 11 Vincristine 10 Gemcitabine 10 Azacitidine 10 pomalidomide 9 Nivolumab 9 Interleukin-2 9 Granulocyte Colony-Stimulating Factor 9 Doxorubicin 9 Calcium Dobesilate 9 carfilzomib 8 Topotecan 8 Methotrexate 8 Everolimus 8 Decitabine 8 Bortezomib 8 Melphalan 7 Cisplatin 7 Vorinostat 6 Injections 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00925275 2010-05-04

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

Cellectar, Inc

Phase 1 Completed

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡